Predicting HER2 status in esophagogastric cancer: Development and validation of an easy-to-use nomogram

Introduction: HER2 currently represents the only available predictive biomarker in advanced esophagogastric cancer. Trastuzumab plus chemotherapy is the standard of care in tumors carrying HER2 protein overexpression by immunohistochemistry (IHC) or gene amplification by in situ hybridization (ISH). However, heterogeneity in protein expression, lack of adequate tumor samples for analyses and the need for rapid target assessment for patient...